FDA Grants Fast Track Designation To Lipocine's LPCN 1148 For Treating Sarcopenia In Patients With Decompensated Cirrhosis, Targeting First-In-Class Status With Novel Mechanism Of Action
FDA Grants Fast Track Designation To Lipocine's LPCN 1148 For Treating Sarcopenia In Patients With Decompensated Cirrhosis, Targeting First-In-Class Status With Novel Mechanism Of Action
FDA授予Lipocine的LPCN 1148在治疗失代偿性肝硬化患者的肌肉减少症方面快速通道认证，旨在通过新颖的作用机制实现首创药物地位。
FDA Grants Fast Track Designation To Lipocine's LPCN 1148 For Treating Sarcopenia In Patients With Decompensated Cirrhosis, Targeting First-In-Class Status With Novel Mechanism Of Action
FDA授予Lipocine的LPCN 1148在治疗失代偿性肝硬化患者的肌肉减少症方面快速通道认证，旨在通过新颖的作用机制实现首创药物地位。
资讯热榜
更新时间